Loader Michelle, Moravek Rudolph, Witowski Sarah E, Driscoll Lynette M
At the University of Colorado School of Medicine in Aurora, Colo., Michelle Loader is a senior instructor in the Department of Medicine, Division of Hospital Gastroenterology and Hepatology; Rudolph Moravek and Sarah E. Witowski are instructors in the Department of Medicine, Division of Hospital Medicine; and Lynette M. Driscoll is an instructor in the Department of Surgery, Division of Transplant Surgery. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2019 Nov;32(11):15-20. doi: 10.1097/01.JAA.0000586300.88300.84.
Viral hepatitis remains a significant public health problem in the United States, despite advances in antiviral therapy and effective vaccines. According to the CDC, about 20,000 deaths each year are attributed to viral hepatitis, and 5 million people are chronically infected and at risk for serious liver disease and hepatocellular cancer. This article reviews the three most common causes of viral hepatitis, screening guidelines, clinical features, medical management, approaches for primary prevention, and the natural history of untreated disease.
尽管抗病毒治疗取得进展且有有效的疫苗,但病毒性肝炎在美国仍然是一个重大的公共卫生问题。根据美国疾病控制与预防中心(CDC)的数据,每年约有2万例死亡归因于病毒性肝炎,500万人受到慢性感染,面临严重肝病和肝细胞癌的风险。本文回顾了病毒性肝炎最常见的三种病因、筛查指南、临床特征、医疗管理、一级预防方法以及未治疗疾病的自然史。